ENDPOINTS

#ASCO25: AstraZeneca details Phase 3 data for oral SERD 'switching' regimen

CHICAGO — AstraZeneca is planting its flag in the oral SERD space, touting positive Phase 3 breast cancer data for a program it expects to exceed more than $5 billion in annual peak sales. The trial ...

Jun 1, 2025 - 13:04
 0
#ASCO25: AstraZeneca details Phase 3 data for oral SERD 'switching' regimen
CHICAGO — AstraZeneca is planting its flag in the oral SERD space, touting positive Phase 3 breast cancer data for a program it expects to exceed more than $5 billion in annual peak sales. The trial ...
Read More

Tags:

Previous Article

How to reset your terrible streaming recommendations

Next Article

#ASCO25: Researchers debate how best to use checkpoint drugs in earlier cancers

Related Posts

Laid-off FDA workers wait in limbo, collecting pay and wondering what's next

Laid-off FDA workers wait in limbo, collecting pay and ...

Jun 2, 2025  0

Reproductive health biotech ReproNovo closes $65M Series A

Reproductive health biotech ReproNovo closes $65M Series A

May 21, 2025  0

Geoffrey Porges exits Schrödinger with CFO swap; A new board seat for AstraZeneca's Pascal Soriot

Geoffrey Porges exits Schrödinger with CFO swap; A new ...

May 23, 2025  0